Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Study Halted; ‘Hyperprogression’ Seen With Nivolumab for R/R PTCL

Publish date:: December 9, 2019

Key clinical point: The study was halted early because of short-lived response and disease hyperprogression.

Major finding: Median progression-free survival was 2.7 months, and median overall survival was 6.7 months

Study details: An interim analysis of a phase 2 trial with 12 patients with peripheral T-cell lymphomas.

Disclosures: The study was supported by Bristol-Myers Squibb. Dr. Bennani reported research funding and advisory board activities for Bristol-Myers Squibb and others.

Citation:

Bennani NN et al. ASCO 2019, Abstract 467.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Aggressive Lymphomas

Study Halted; ‘Hyperprogression’ Seen With Nivolumab for R/R PTCL,

CAR T-Cell Therapy Found Safe, Effective For HIV-Associated Lymphoma,

Bispecific CAR T-cell Therapy Yields Complete Responses in Relapsed/Refractory non-Hodgkin Lymphomas,

5F9 Plus Rituximab Take a Bite Out of Drug-Resistant NHL,

‘Encouraging’ Responses Seen With Durvalumab Plus R-CHOP in DLBCL,